CXL is the first FDA approved treatment for Keratoconus, a progressive disease of the cornea. Combining the use of UVA light and riboflavin drops, CXL stops disease progression and improves corneal curvature.
- Clinical Research Site
CXL is the first FDA approved treatment for Keratoconus, a progressive disease of the cornea. Combining the use of UVA light and riboflavin drops, CXL stops disease progression and improves corneal curvature.